RxDoctor Payments Data

Melinda Zamora

Psychiatric/Mental Health · San Antonio, TXNPI 1184351330

Payments from drug & device makers

$4,823in general payments, 2019–2025

Across 228 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$547
  • AbbVie$442
  • Otsuka America Pharmaceutical, Inc.$413
  • Supernus Pharmaceuticals, Inc.$330
  • Axsome Therapeutics, Inc.$313
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$4,811100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,823 in reported general payments places this provider in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$50,493
Medicare patients
65
Services billed
658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole17$35,830
Lurasidone Hcl22$12,086
Atomoxetine Hcl24$3,543
Duloxetine Hcl29$3,448
Fluoxetine Hcl31$2,577
Aripiprazole22$1,742
Hydroxyzine Hcl111$1,728
Fluvoxamine Maleate28$1,484
Quetiapine Fumarate59$1,378
Buspirone Hcl86$1,338
Bupropion XlBupropion Hcl54$1,309
Lamotrigine120$996
Venlafaxine Hcl ErVenlafaxine Hcl16$925
Sertraline Hcl87$773
Oxcarbazepine14$742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$413$35,83017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →